High-efficiency lentiviral transduction of primary human CD34+ hematopoietic cells with low-dose viral inocula

Sang Won Park, Chul Woong Pyo, Sang-Yun Choi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Lentivirus-based vectors have the potential to transduce non-dividing primary stem cells. However, primary cells tend to be less susceptible to manipulation and require a high concentration of virus inoculum. Furthermore, increasing the concentration of the lentivirus inoculum may raise safety risks. Therefore, to develop a technique that allows high transduction efficiency at low multiplicities of infection (MOIs), we optimized a lentivirus-based system for cell lines and primary cells by determining the best condition using various parameters. When progenitor cell assays were conducted using human CD34+ bone marrow and mononuclear cells, the transduction condition yielded a great number of eGFP+ colonies with lower-dose viral inocula compared to that of current lentivirus-based transduction technologies. In conclusion, this system is anticipated to produce stable expression of a gene introduced into primary cells for preclinical studies with lower safety risks.

Original languageEnglish
Pages (from-to)281-288
Number of pages8
JournalBiotechnology Letters
Volume37
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

Lentivirus
Stem Cells
Safety
Bone Marrow Cells
Viruses
Technology
Gene Expression
Cell Line
Infection

Keywords

  • CD34 bone marrow
  • Gene therapy
  • Hematopoietic cells
  • Progenitor cell assay
  • Pseudotyped lentiviral vector
  • Transduction efficiency
  • Viral inoculum

ASJC Scopus subject areas

  • Biotechnology

Cite this

High-efficiency lentiviral transduction of primary human CD34+ hematopoietic cells with low-dose viral inocula. / Park, Sang Won; Pyo, Chul Woong; Choi, Sang-Yun.

In: Biotechnology Letters, Vol. 37, No. 2, 2014, p. 281-288.

Research output: Contribution to journalArticle

@article{ea95a8b11b9b4c2eb9508ada723e0aea,
title = "High-efficiency lentiviral transduction of primary human CD34+ hematopoietic cells with low-dose viral inocula",
abstract = "Lentivirus-based vectors have the potential to transduce non-dividing primary stem cells. However, primary cells tend to be less susceptible to manipulation and require a high concentration of virus inoculum. Furthermore, increasing the concentration of the lentivirus inoculum may raise safety risks. Therefore, to develop a technique that allows high transduction efficiency at low multiplicities of infection (MOIs), we optimized a lentivirus-based system for cell lines and primary cells by determining the best condition using various parameters. When progenitor cell assays were conducted using human CD34+ bone marrow and mononuclear cells, the transduction condition yielded a great number of eGFP+ colonies with lower-dose viral inocula compared to that of current lentivirus-based transduction technologies. In conclusion, this system is anticipated to produce stable expression of a gene introduced into primary cells for preclinical studies with lower safety risks.",
keywords = "CD34 bone marrow, Gene therapy, Hematopoietic cells, Progenitor cell assay, Pseudotyped lentiviral vector, Transduction efficiency, Viral inoculum",
author = "Park, {Sang Won} and Pyo, {Chul Woong} and Sang-Yun Choi",
year = "2014",
doi = "10.1007/s10529-014-1678-z",
language = "English",
volume = "37",
pages = "281--288",
journal = "Biotechnology Letters",
issn = "0141-5492",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - High-efficiency lentiviral transduction of primary human CD34+ hematopoietic cells with low-dose viral inocula

AU - Park, Sang Won

AU - Pyo, Chul Woong

AU - Choi, Sang-Yun

PY - 2014

Y1 - 2014

N2 - Lentivirus-based vectors have the potential to transduce non-dividing primary stem cells. However, primary cells tend to be less susceptible to manipulation and require a high concentration of virus inoculum. Furthermore, increasing the concentration of the lentivirus inoculum may raise safety risks. Therefore, to develop a technique that allows high transduction efficiency at low multiplicities of infection (MOIs), we optimized a lentivirus-based system for cell lines and primary cells by determining the best condition using various parameters. When progenitor cell assays were conducted using human CD34+ bone marrow and mononuclear cells, the transduction condition yielded a great number of eGFP+ colonies with lower-dose viral inocula compared to that of current lentivirus-based transduction technologies. In conclusion, this system is anticipated to produce stable expression of a gene introduced into primary cells for preclinical studies with lower safety risks.

AB - Lentivirus-based vectors have the potential to transduce non-dividing primary stem cells. However, primary cells tend to be less susceptible to manipulation and require a high concentration of virus inoculum. Furthermore, increasing the concentration of the lentivirus inoculum may raise safety risks. Therefore, to develop a technique that allows high transduction efficiency at low multiplicities of infection (MOIs), we optimized a lentivirus-based system for cell lines and primary cells by determining the best condition using various parameters. When progenitor cell assays were conducted using human CD34+ bone marrow and mononuclear cells, the transduction condition yielded a great number of eGFP+ colonies with lower-dose viral inocula compared to that of current lentivirus-based transduction technologies. In conclusion, this system is anticipated to produce stable expression of a gene introduced into primary cells for preclinical studies with lower safety risks.

KW - CD34 bone marrow

KW - Gene therapy

KW - Hematopoietic cells

KW - Progenitor cell assay

KW - Pseudotyped lentiviral vector

KW - Transduction efficiency

KW - Viral inoculum

UR - http://www.scopus.com/inward/record.url?scp=84925488487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925488487&partnerID=8YFLogxK

U2 - 10.1007/s10529-014-1678-z

DO - 10.1007/s10529-014-1678-z

M3 - Article

C2 - 25257593

AN - SCOPUS:84925488487

VL - 37

SP - 281

EP - 288

JO - Biotechnology Letters

JF - Biotechnology Letters

SN - 0141-5492

IS - 2

ER -